Although additional confirmation of this activity will help elucidate overall intracranial disease outcomes, this report underscores the potential of selective RET inhibition as a means of treating and preventing the occurrence of disease in the CNS in patients with RET-dependent cancers of any histology. The gene discussed is RET; the disease is cancer.